[Hyperthermic immuno-cellular therapy-basic and clinical study].
BASIC: We treated mice inoculated LLC tumors with hyperthermia or activated lymphocytes. Both of hyperthermia and activated lymphocytes therapy reduced not only a tumor growth but also lung metastasis. And a combination therapy of hyperthermia and activated lymphocytes therapy reduced more of the tumor growth and lung metastasis synergistically. CLINICAL: We proceeded with hyperthermia (HT) for 472 cancer patients and activated lymphocytes (CAT) therapy for 384 patients and dendritic cell (DC) therapy for 94 patients. Two-hundred-thirty-eight patients of them underwent a combination therapy with hyperthermia and CAT therapy. And 92 patients received a combination therapy with hyperthermia and DC therapy. We proceeded with hyperthermia or immunotherapy for 526 cancer patients. And we have 67 clinical benefit cases including 8 complete response (CR) cases. These basic and clinical results indicate an effectiveness of a combination therapy with hyperthermia and cellular-immunotherapy for cancer patients.
Takeda
Tsutomu
T
Osaka Cancer Immuno-Chemotherapy Center, Keisenkai.
Fukunaga
Kanae
K
Miyazawa
Kenki
K
Takahashi
Toru
T
Takeda
Hiroko
H
Takeda
Yutaka
Y
Tanigawa
Keishi
K
Morisaki
Takashi
T
Yamamoto
Itsuo
I
Hasegawa
Takeo
T
D000818:Animals; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D007167:Immunotherapy; D008213:Lymphocyte Activation / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*